Currently Viewing:
Newsroom
Currently Reading
Updates to Treatment Options During Breast Cancer Awareness Month
October 02, 2017 – Surabhi Dangi-Garimella, PhD
Study Finds Outreach Interventions Effective for CRC Screenings
October 01, 2017 – Alison Rodriguez
5 Takeaways for Payers and Providers From the NCCN Meeting on Quality Metrics
September 29, 2017 – Surabhi Dangi-Garimella, PhD
Navigating the Quality Landscape in Oncology: Pitfalls and Lessons Learned
September 29, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: September 29, 2017
September 29, 2017
Report Finds Hospitals Costlier for Cancer Care Than Community Practices
September 29, 2017 – Christina Mattina
Researchers Categorize Incurable Childhood Brain Tumors as Separate Cancer Types
September 28, 2017 – Christina Mattina
Early Imaging Can Identify Positive Immunotherapy Responders in Advanced Melanoma
September 28, 2017 – Surabhi Dangi-Garimella, PhD
Dr Michael Feld: New Liquid ADHD Treatment Has Benefits for Both Patients and Physicians
September 27, 2017

Updates to Treatment Options During Breast Cancer Awareness Month

Surabhi Dangi-Garimella, PhD
October is breast cancer awareness month, and as September ended, a new treatment received the FDAs approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.
October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.

On September 28, the FDA approved abemaciclib (Verzenio) for the treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer that has progressed on endocrine therapy. A CDK4/6 inhibitor, abemaciclib is currently approved in combination with fulvestrant in patients who have progressed on endocrine therapy. It is also approved to be given alone in combination with endocrine therapy and chemotherapy following metastasis.

Abemaciclib was evaluated in combination with fulvestrant in a randomized trial of 669 patients with HR-positive, HER2-negative breast cancer that had progressed following treatment with endocrine therapy and who had not received chemotherapy following metastasis. Median progression-free survival was 16.4 months in the abemaciclib plus chemotherapy arm, compared with 9.4 months in patients treated with a placebo and chemotherapy.

Abemaciclib as a stand-alone was evaluated in a single-arm study in 132 patients with HR-positive, HER2-negative breast cancer that had progressed on endocrine therapy and chemotherapy following metastasis. Nearly 20% of patients on abemaciclib presented with partial or complete shrinkage of their tumors for a median period of 8.6 months.

On September 29, Roche announced that the FDA had accepted a supplemental Biologics License Application (sBLA) for pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and chemotherapy for adjuvant treatment of HER2-positive early breast cancer. While the FDA has already granted an accelerated approval for the combination, the current submission is aimed at converting it to a full approval.

The decision date for the sBLA is January 28, 2018.  

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up